Selected Grants
A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection (AMR) (TRANSCEND)
Clinical TrialPrincipal Investigator · Awarded by Biogen MA, Inc. · 2025 - 2030Targeting the B Cell Response to Treat Antibody-Mediated Rejection
ResearchCo Investigator · Awarded by National Institutes of Health · 2021 - 2028External Relationships
- Biogen
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.